Hemostemix Inc. (CVE:HEM – Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as C$0.10 and last traded at C$0.09, with a volume of 1500 shares trading hands. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The company’s 50 day simple moving average is C$0.08 and its 200 day simple moving average is C$0.06. The company has a market capitalization of C$7.84 million, a PE ratio of -4.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- How to Buy Cheap Stocks Step by Step
- What a Trump Win Looks Like for the Market Now and Into 2025
- How to Use the MarketBeat Stock Screener
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- How to Use the MarketBeat Dividend Calculator
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
